- Home
- NEGG vs PRQR Comparison
NEGG vs PRQR Comparison
Compare NEGG & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEGG | PRQR |
|---|---|---|
| Founded | 2001 | 2012 |
| Country | United States | Netherlands |
| Employees | 714 | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 222.7M | 262.5M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | NEGG | PRQR |
|---|---|---|
| Price | $9.78 | $1.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $7.78 |
| AVG Volume (30 Days) | 26.6K | ★ 968.3K |
| Earning Date | 08-27-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $8.25 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.29 | $1.20 |
| 52 Week High | $96.29 | $2.81 |
Technical Indicators
Market Signals| Indicator | NEGG | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 33.89 | 39.53 |
| Support Level | N/A | N/A |
| Resistance Level | $20.11 | $1.99 |
| Average True Range (ATR) | 0.73 | 0.10 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 19.58 | 39.29 |
Price Performance
Historical ComparisonAbout NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products, and provides certain third-party logistics services globally. Geographically, it operates in the United States, Canada, and the Rest of the world.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.